DPP-4抑制剂曲格列汀治疗2型糖尿病的临床应用评价

发布时间：2019-03-20 20:24

【摘要】：目的研究2型糖尿病通过DPP-4抑制剂曲格列汀来进行治疗,所取得的临床应用效果,并对其进行评价。方法通过对我国以及外国曲格列汀对2型糖尿病患者治疗的文献进行检索,将曲格列汀的各个方面的临床应用进行研究和评价。结果 2型糖尿病患者通过1次/周口服曲格列汀来进行治疗和1次/d服用1次阿格列汀来进行治疗,2种药物取得的治疗效果大致相同;2型糖尿病患者通过服用100 mg的曲格列汀,最长的达峰时间为1.3 h,3 d内的半衰期平均为18.5 h,7 d内的半衰期平均为54.3 h,患者均没有产生明显的蓄积效应;通过曲格列汀治疗,空腹时的血糖浓度均得到明显的降低效果,用食2 h后,患者的血糖浓度与用药时曲线下面积(AUC)得到显著改善,曲格列汀的剂量与效果呈正比;服用曲格列汀后体内的的糖化血红蛋白(HbA1c)含量明显改善;Ⅱ期剂量研究:患者通过服用剂量依次增加的曲格列汀,不良反应概率达到:37%、39%、40%、50%、51%,不良反应最常见为鼻咽炎,鼻咽炎的程度大多是轻度到中度,其中服用50 mg药量的患者中小肠结肠炎患者2例,服用200 mg药量的患者中糖尿病坏疽患者有2例,Ⅲ期验证研究:常见不良症状依旧是轻度或中度鼻咽炎。结论 2型糖尿病患者通过服用DPP-4抑制剂曲格列汀,药物疗效显著,该药在临床上的应用具有重要意义。
[Abstract]:Objective to study the clinical effects of treatment of type 2 diabetes mellitus (T2DM) by DPP-4 inhibitor trasiglitine and to evaluate the clinical efficacy of Teglitine in the treatment of type 2 diabetes mellitus. Methods the clinical application of trasiglitine in patients with type 2 diabetes mellitus was studied and evaluated by searching the literature on the treatment of type 2 diabetes mellitus in China and foreign countries. Results patients with type 2 diabetes were treated with trasiglitine once a week and aceglitine once a day. The therapeutic effects of the two drugs were approximately the same. The longest peak time of type 2 diabetic patients was 1.3h, the average half-life within 3 days was 18.5 hours, and the average half-life within 7 days was 54.3 hours. There was no significant accumulative effect in patients with type 2 diabetes mellitus. After 2 hours of treatment, the blood glucose concentration of the patients was significantly improved with the area under the curve of treatment (AUC), and the dose of trasiglitine was in direct proportion to the effect. 2 hours after the treatment, the blood glucose concentration of the patients was significantly improved with the decrease of the fasting blood glucose concentration. The content of glycosylated hemoglobin (HbA1c) in the body was significantly improved after the administration of trasiglitine. Phase II dose study: the adverse reaction probability was 37%, 39%, 40%, 50%, 51%, and the most common side effects were nasopharyngitis, and the degree of nasopharyngitis was mostly mild to moderate, and the adverse reaction probability was 37%, 39%, 40%, 50%, 51%. Among them, 2 patients with enterocolitis and 2 patients with diabetes gangrene were treated with 50 mg and 2 patients with diabetes gangrene. Phase 鈪，

本文编号：2444601